Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Tryptamine Therapeutics ( (AU:TYP) ) has provided an announcement.
Tryptamine Therapeutics Limited has announced a change in the director’s interest in securities. Gage Jull, a director of the company, has experienced a lapse in director options due to the vesting conditions not being met as of December 31, 2024. This change does not affect the current number of ordinary fully paid shares held by the director but results in the reduction of 1,000,000 previously held director options.
More about Tryptamine Therapeutics
YTD Price Performance: -7.50%
Average Trading Volume: 4,025,654
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$47.23M
For an in-depth examination of TYP stock, go to TipRanks’ Stock Analysis page.
